Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1646 1674 1681 1797
This examiner grants 64% of resolved cases
Zachary C. Howard operates within Tech Center 1700 and Art Unit 1646. The examiner has handled 964 resolved cases. The data shows an allowance rate of 64.0 percent. This figure provides a metric for applicants seeking patent grants. The median days to allowance is 1034. This timeframe indicates the prosecution process for successful applications. Practitioners should prepare for a duration matching this figure when working on cases in this art unit.
The interview lift for Howard is 37.9 percent. This percentage indicates that conducting an interview increases the probability of securing an allowance. The 37.9 percent interview lift is smaller than the overall 64.0 percent allowance rate. Across the 964 resolved cases, the median days to allowance of 1034 serves as a benchmark for managing client expectations. In Art Unit 1646, the interview lift suggests that direct communication is a strategy to consider. This profile provides a baseline for success in Tech Center 1700.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18174889 | METHODS FOR PRODUCING ANTIBODIES | Non-Final OA | Genentech, Inc. |
| 18033746 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH TGF-BETA ACTIVITY | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18278676 | FLUORESCENT BIOSENSORS AND METHODS OF USE FOR DETECTING CELL SIGNALING EVENTS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18031840 | CD47 BLOCKADE AND COMBINATION THERAPIES THEREOF FOR REDUCTION OF VASCULAR INFLAMMATION | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18265338 | AN ANTIBODY AGAINST P-CADHERIN AND USES THEREOF | Final Rejection | WUXI BIOLOGICS IRELAND LIMITED |
| 18776820 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18674399 | METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18252005 | METHODS AND SYSTEMS FOR CLASSIFICATION AND TREATMENT OF SMALL CELL LUNG CANCER | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18026696 | THERAPEUTIC AGENTS AND USES THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18251913 | ANTIBODY Fc VARIANTS | Final Rejection | Novartis AG |
| 18187242 | USE OF CANAKINUMAB | Non-Final OA | Novartis AG |
| 18558013 | Lipid Nanoparticle Therapeutics that Evade the Immune Response | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18281460 | TARGET ANALYTE DETECTION METHOD BASED ON PROXIMITY PROTEOLYSIS REACTION | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18770259 | ASGR INHIBITORS | Non-Final OA | Amgen Inc. |
| 18251871 | THERAPEUTIC TARGETING OF MESOTHELIN IN ACUTE MYELOID LEUKEMIA WITH CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | Final Rejection | FRED HUTCHINSON CANCER CENTER |
| 18546384 | CELL THERAPY COMPOSITIONS AND METHODS FOR MODULATING TGF-B SIGNALING | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18686862 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Non-Final OA | Academia Sinica |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy